These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 12812118)
1. [Finasteride: 10 years of clinical use. Systematic review of the literature]. Jiménez Cruz JF; Quecedo Gutiérrez L; Del Llano Señarís J Actas Urol Esp; 2003 Mar; 27(3):202-15. PubMed ID: 12812118 [TBL] [Abstract][Full Text] [Related]
2. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Marberger MJ Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579 [TBL] [Abstract][Full Text] [Related]
3. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762 [TBL] [Abstract][Full Text] [Related]
4. 5alpha-reductase inhibitors: what role should they play? Kaplan SA Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255 [TBL] [Abstract][Full Text] [Related]
5. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Wilde MI; Goa KL Drugs; 1999 Apr; 57(4):557-81. PubMed ID: 10235693 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J; Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of different drugs on the treatment of benign prostate hyperplasia]. Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376 [TBL] [Abstract][Full Text] [Related]
8. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia]. Djavan B; McConnell J Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401 [TBL] [Abstract][Full Text] [Related]
9. Finasteride for BPH. Johnson KH; Casey CM J Fam Pract; 1998 Jun; 46(6):455-6. PubMed ID: 9638104 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291 [TBL] [Abstract][Full Text] [Related]
11. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354 [TBL] [Abstract][Full Text] [Related]
12. The effect of finasteride on prostate specific antigen: review of available data. Guess HA; Gormley GJ; Stoner E; Oesterling JE J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873 [TBL] [Abstract][Full Text] [Related]
13. [Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms]. Wirth MP; Helke C; Froschermaier SE Urologe A; 1997 Jan; 36(1):35-9. PubMed ID: 9123679 [TBL] [Abstract][Full Text] [Related]
14. Finasteride in the treatment of benign prostatic hyperplasia. Ekman P; Andersen JT; Wolf H Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328 [TBL] [Abstract][Full Text] [Related]
15. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706 [TBL] [Abstract][Full Text] [Related]
16. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. Wilt TJ; Ishani A; Stark G; MacDonald R; Lau J; Mulrow C JAMA; 1998 Nov; 280(18):1604-9. PubMed ID: 9820264 [TBL] [Abstract][Full Text] [Related]
17. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine]. Loran OB; Pushkar' DIu; Rasner PI Urologiia; 2002; (1):19-22. PubMed ID: 11877966 [TBL] [Abstract][Full Text] [Related]
18. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Roehrborn CG; Lee M; Meehan A; Waldstreicher J; Urology; 2003 Nov; 62(5):894-9. PubMed ID: 14624915 [TBL] [Abstract][Full Text] [Related]
19. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Vaughan D; Imperato-McGinley J; McConnell J; Matsumoto AM; Bracken B; Roy J; Sullivan M; Pappas F; Cook T; Daurio C; Meehan A; Stoner E; Waldstreicher J Urology; 2002 Dec; 60(6):1040-4. PubMed ID: 12475666 [TBL] [Abstract][Full Text] [Related]
20. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. Wilt TJ; Howe W; MacDonald R BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]